文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

重症AKI患者血清IL-17水平更高且与不良结局相关

Serum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomes.
PubMed 文献 · Crit Care · 2022-04-14
一句话结论重症患者AKI诊断或ICU入住时血清IL-17A升高,每升高1倍与住院死亡(aOR 1.35)和MAKE(aOR 1.26)独立相关。

多中心前瞻性研究纳入299例ICU患者,比较AKI 2-3期与无AKI患者血清IL-17A水平。AKI患者在T1(AKI诊断或ICU入住后24-48小时)IL-17A为1918.6 fg/ml(692.0-5860.9),高于无AKI患者的623.1 fg/ml(331.7-1503.4),p<0.001;T2(5-7天后)为2167.7 fg/ml(839.9-4618.9)对1193.5 fg/ml(523.8-2198.7),p=0.006。T1每1倍升高的IL-17A与住院死亡(aOR 1.35,95%CI 1.06-1.73)和MAKE(aOR 1.26,95%CI 1.02-1.55)独立相关,最高三分位与最低三分位相比MAKE风险aOR 3.03(95%CI 1.34-6.87)。AKI状态未修饰这些关联;死亡或发生MAKE者T2 IL-17A仍显著升高。

要点

  • AKI 2-3期患者T1血清IL-17A为1918.6 fg/ml(692.0-5860.9),显著高于无AKI患者的623.1 fg/ml(331.7-1503.4),p<0.001。
  • T1每1倍升高的IL-17A与住院死亡独立相关(aOR 1.35,95%CI 1.06-1.73),与MAKE独立相关(aOR 1.26,95%CI 1.02-1.55)。
  • IL-17A最高三分位(对最低三分位)与MAKE风险独立相关(aOR 3.03,95%CI 1.34-6.87)。
  • AKI状态未修饰IL-17A与死亡或MAKE的关联。
  • 死亡或发生MAKE的患者在T2(5-7天后)IL-17A仍显著升高。

适用人群与场景

  • 多中心前瞻性研究纳入的ICU患者,包括AKI 2期或3期患者以及无AKI患者。
  • 样本采集时间:AKI患者在AKI诊断后24-48小时(T1),无AKI患者在ICU入住后24-48小时(T1),以及5-7天后(T2)。

诊断标准与关键阈值

  • AKI分期采用AKI 2期或3期。
  • MAKE定义为死亡、依赖肾脏替代治疗或出院后90天内eGFR较基线下降≥30%的复合终点。

研究设计与关键结果

  • 研究类型:多中心前瞻性研究,共评估299例患者。
  • AKI患者IL-17A高于无AKI患者:T1为1918.6 fg/ml(692.0-5860.9)对623.1 fg/ml(331.7-1503.4),p<0.001;T2为2167.7 fg/ml(839.9-4618.9)对1193.5 fg/ml(523.8-2198.7),p=0.006。
  • T1时IL-17A最高三分位(对较低三分位)的患者病情严重程度评分和合并症评分更高。
  • T1每1倍升高的血清IL-17A与住院死亡风险独立相关(aOR 1.35,95%CI 1.06-1.73),与MAKE风险独立相关(aOR 1.26,95%CI 1.02-1.55)。
  • IL-17A最高三分位(对最低三分位)与MAKE风险独立相关(aOR 3.03,95%CI 1.34-6.87)。
  • AKI状态未修饰上述关联。
  • 死亡或发生MAKE的患者在T2时IL-17A水平仍显著升高。

证据类型、等级与局限

  • 证据类型:多中心前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,AKI诊断或ICU入住时测得的血清IL-17A水平在重症AKI患者中差异性升高,且与住院死亡和MAKE独立相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Interleukin-17 (IL-17) antagonism in rats reduces the severity and progression of AKI. IL-17-producing circulating T helper-17 (TH17) cells is increased in critically ill patients with AKI indicating that this pathway is also activated in humans. We aim to compare serum IL-17A levels in critically ill patients with versus without AKI and to examine their relationship with mortality and major adverse kidney events (MAKE).

METHODS: Multicenter, prospective study of ICU patients with AKI stage 2 or 3 and without AKI. Samples were collected at 24-48 h after AKI diagnosis or ICU admission (in those without AKI) [timepoint 1, T1] and 5-7 days later [timepoint 2, T2]. MAKE was defined as the composite of death, dependence on kidney replacement therapy or a reduction in eGFR of ≥ 30% from baseline up to 90 days following hospital discharge.

RESULTS: A total of 299 patients were evaluated. Patients in the highest IL-17A tertile (versus lower tertiles) at T1 had higher acuity of illness and comorbidity scores. Patients with AKI had higher levels of IL-17A than those without AKI: T1 1918.6 fg/ml (692.0-5860.9) versus 623.1 fg/ml (331.7-1503.4), p < 0.001; T2 2167.7 fg/ml (839.9-4618.9) versus 1193.5 fg/ml (523.8-2198.7), p = 0.006. Every onefold higher serum IL-17A at T1 was independently associated with increased risk of hospital mortality (aOR 1.35, 95% CI: 1.06-1.73) and MAKE (aOR 1.26, 95% CI: 1.02-1.55). The highest tertile of IL-17A (vs. the lowest tertile) was also independently associated with higher risk of MAKE (aOR 3.03, 95% CI: 1.34-6.87). There was no effect modification of these associations by AKI status. IL-17A levels remained significantly elevated at T2 in patients that died or developed MAKE.

CONCLUSIONS: Serum IL-17A levels measured by the time of AKI diagnosis or ICU admission were differentially elevated in critically ill patients with AKI when compared to those without AKI and were independently associated with hospital mortality and MAKE.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Collett JA, Ortiz-Soriano V, Li X, et al. Serum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomes. Crit Care. 2022. PMID: 35422004. doi:10.1186/s13054-022-03976-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。